In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even ...

Africa bears a disproportionate infectious disease burden, with HIV, tuberculosis, and malaria posing ongoing threats ...

A group of academics is arguing that countries seeking access to a groundbreaking HIV prevention drug from Gilead Sciences ...

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $105.25, denoting a +2% change from the preceding trading day.

ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 ...

With that said, let's consider two top dividend stocks that should navigate the current storm relatively well and continue ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...

A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s ...

NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double ...

Human immunodeficiency virus, if untreated, causes acquired immunodeficiency syndrome (AIDS), and death. HIV is almost entirely preventable by using condoms, or by taking PrEP drugs. PrEP drugs do not ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...